Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Alpha1-Antitrypsin Deficiency

In brief

The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually end stage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver. People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran, whether participants tolerate the treatment and if there are any effects on liver scarring. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study.

Key facts

Study ID

NCT06165341

Run by

Takeda

People needed

50

Starts

2024-03-01

Expected to finish

2028-08-26

Last updated by the study team

2026-03-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• In the opinion of the investigator, the participant is capable of understanding and fully complying with the protocol requirements and adhering to the protocol schedule.
• The participant is able to read, understand, and complete the study questionnaires electronically per the investigator's judgment.
• The participant signs and dates a written Informed Consent Form (ICF). Any required privacy authorization should also be signed before the initiation of any study procedures.
• The participant, of any sex, is aged 18 to 75 years, inclusive.
• The participant must have a diagnosis of the protease inhibitor Z mutation (PiZZ) genotype AATD. A diagnosis of PiZZ from source-verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted.
• The participant's liver biopsy core samples collected as per protocol requirements.
• The participant has evidence of METAVIR stage F1 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading from a previous biopsy conducted within 1 year before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual.
• The participant has a pulmonary status that meets the protocol requirements.
• It must be confirmed that the participant does not have hepatocellular carcinoma (HCC).
• Any participant who is taking statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or beta-1 selective adrenergic receptor inhibitors must have been receiving a stable dose of these medications for at least 8 weeks before randomization. All attempts are to be made for the participant to continue the same dose of the medication for the duration of study participation.
• An adult participant must have a body mass index (BMI) between 18 and 39 kilogram per meter square (kg/m\^2), inclusive.
• The participant has a 12-lead electrocardiogram at screening that, in the opinion of the investigator, has no abnormalities that could compromise the participant's safety in this study.
• The participant is a nonsmoker.
• If the participant was being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose systemic corticosteroids (prednisone less than or equal to [<=10] milligrams per day [mg/d] or its equivalent), the doses of the participant's medications must have remained unchanged for greater than or equal to (>=) 4 weeks before screening.
• The participant must have suitable venous access for blood sampling.
• A person of childbearing potential (POCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 before dosing.
• The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study and for 6 months after the last dose of study medication. The participant must not donate sperm for at least 6 months after the last dose of study medication.

You may not qualify if…

• The participant has evidence of >= F2 fibrosis based on liver biopsy during the screening period.
• The participant has a history of liver decompensating events.
• The participant has a history of varices based on a previous esophagogastroduodenoscopy.
• The participant has portal vein thrombosis.
• The participant has undergone a prior trans-jugular portosystemic shunt procedure.
• The participant has evidence of other forms of chronic liver diseases.
• The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with curatively treated malignancies who have no evidence of metastatic disease and disease-free interval greater than (>) 1 year may be enrolled after approval by the medical monitor.
• The participant has an abnormal finding of clinical relevance at the screening evaluation and before administration of the first dose of study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results.
• The participant has any laboratory abnormalities at screening and before the first dose of the study drug that meet protocol parameters.
• The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals.
• The participant has a recent lower respiratory tract infection, such as pneumonia, within the last 6 months before screening. The participant may be screened earlier based on principal investigator (PI) assessment of clinical recovery and return to baseline pulmonary function in discussion with the medical monitor.
• The participant has a history of frequent pulmonary exacerbations (>=2 moderate or severe exacerbations within 52 weeks before screening).
• The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be rescreened after the clinical resolution of an exacerbation).
• The participant is receiving long-term, around-the-clock oxygen supplementation or supplemental oxygen with continuous positive airway pressure (CPAP) or bilevel positive airway pressure for acute respiratory failure. The following conditions are allowable for the participant to enter screening: short-term use of oxygen supplementation (example, for the management of acute chronic obstructive pulmonary disease [COPD] exacerbation) or CPAP for obstructive sleep apnea.
• The participant has human immunodeficiency virus (HIV) infection as shown by the presence of anti-HIV antibody (seropositive).
• The participant is seropositive for hepatitis B virus (HBV surface antigen positive and/or HBV core antibody positive without HBV surface antibody at screening) or hepatitis C virus (HCV) (detectable HCV Ribonucleic Acid [RNA] at screening). Cured HCV (positive antibody test without detectable HCV RNA for at least 6 months after treatment) is acceptable.
• The participant has unstable, poorly controlled, or severe hypertension. Participants may be rescreened once their blood pressure (BP) is successfully controlled.
• The participant has a history of torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia), heart block (excluding first-degree block, being PR interval prolongation only), congenital long QT syndrome or new ST-segment elevation or depression or a new Q wave on ECG. Participants with a history of atrial arrhythmias should be discussed with the medical monitor.
• The participant has symptomatic heart failure (per New York Heart Association guidelines), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction less than [<] 20 percent [%]), transient ischemic attack, or cerebrovascular accident within 6 months before screening.
• The participant has a history of major surgery within 12 weeks of screening (or longer, at the discretion of the investigator).
• The participant has a history of more than moderate alcohol consumption within 12 months before the screening visit.
• The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening.
• The participant has previously been treated with fazirsiran or any other RNA interference (RNAi) for alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).
• The participant has a history of hypersensitivity or allergies with any associated excipients of fazirsiran.
• The participant has received an investigational agent or device within 30 days, or 5 half-lives, whichever is longer, before the dosing of study medication or is currently participating in an investigational study involving a therapeutic intervention.

Where it is running

• King's College Hospital — London, United Kingdom (enrolling)
• Mayo Clinic - PPDS — Phoenix, Arizona, United States (enrolling)
• University of Arizona Thomas D. Boyer Liver Institute — Tucson, Arizona, United States (enrolling)
• University of California San Diego — La Jolla, California, United States (enrolling)
• UCLA Pulmonary and Critical Care — Los Angeles, California, United States (enrolling)
• University of California Benioff Children's Hospital — San Francisco, California, United States (enrolling)
• Peak Gastroenterology Associates — Colorado Springs, Colorado, United States (enrolling)
• Schiff Center for Liver Diseases/University of Miami — Miami, Florida, United States (enrolling)
• Indiana University School of Medicine-Indianapolis — Indianapolis, Indiana, United States (enrolling)
• University Of Iowa Hospitals And Clinics — Iowa City, Iowa, United States (enrolling)
• Boston Medical Center — Boston, Massachusetts, United States (enrolling)
• University of Michigan Hospital - 1500 E Medical Center Dr — Ann Arbor, Michigan, United States (enrolling)
• Henry Ford Health System — Novi, Michigan, United States (enrolling)
• Mayo Clinic PPDS — Rochester, Minnesota, United States (enrolling)
• NYU Langone Medical Center — New York, New York, United States (enrolling)
• Columbia University Irving Medical Center — New York, New York, United States (enrolling)
• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States (enrolling)
• Penn State Health Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States (enrolling)
• Texas Liver Institute American Research Corporation — San Antonio, Texas, United States (enrolling)
• Bon Secours St. Mary's Hospital — Newport, Virginia, United States (enrolling)
• LKH-Universitätsklinikum Graz — Graz, Austria (enrolling)
• KABEG - Klinikum Klagenfurt Am Wörthersee — Klagenfurt, Austria (enrolling)
• UZ Antwerpen — Antwerp, Belgium (enrolling)
• UZ Leuven — Leuven, Belgium (enrolling)
• Inspiration Research Limited — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.